• EDAP Reports Second Quarter 2024 Financial Results

    ソース: Nasdaq GlobeNewswire / 28 8 2024 06:00:00   America/Chicago

           

    • Record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% over Q2 2023
    • Record first half 2024 total worldwide revenue of EUR 30.7 million (USD 33.1 million) increased 5.6% over first half 2023
    • Strong Q2 2024 U.S. Focal One® HIFU procedure growth of +63% year-over-year
    • Company to host conference call and webcast today, August 28th, at 8:30 a.m. EDT

    LYON, France, August 28, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2024.

    “We continue to see growing demand for our proprietary and leading Focal One robotic HIFU technology platform. In the second quarter, we placed five Focal One systems, which included placements with two additional National Cancer Institute (NCI) designated comprehensive cancer centers. A growing number of top tier cancer research and treatment centers continue to adopt Focal One to help patients manage their prostate cancer, which reflects the innovation and positive clinical outcomes of our leading robotic HIFU platform,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “We also experienced strong year over year procedure growth, which points towards the growing adoption of robotic HIFU amongst urologists across both academic and community hospitals.

    “There is also an increasing body of clinical evidence that supports the continued adoption of Focal One as a frontline treatment for localized prostate cancer. The final results from the groundbreaking, prospective HIFI study were presented at this year’s EAU and AUA scientific meetings. This data clearly demonstrates that Focal One robotic HIFU is at least as effective as radical prostatectomy as a first line treatment for localized disease, but with the added potential for improved functional outcomes with respect to both the preservation of urinary continence and sexual function. We believe the HIFI study helps pave the way for broader adoption of our HIFU technology. We expect the results from the HIFI study, in combination with the recent investments in our commercial team, should help drive strong adoption of Focal One throughout the second half of the year.”

    Business Update
      

    • On August 27, 2024, Marc Oczachowski resigned as Chairman of the Company’s Board of Directors in order to allow him more time to focus on other endeavors. In order to provide for a smooth transition for the Board of Directors, the effective date of the resignation will be September 30, 2024.

    • On July 8, 2024, the Company appointed Fran Schulz to its Board of Directors. Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies throughout the life sciences industry. She has deep experience guiding companies to execute a broad range of corporate deals including collaboration agreements, corporate spin-offs, reorganizations, and mergers and acquisitions, with personal involvement in over 100 total equity and debt transactions, raising over $15 billion in aggregate. 
    • On August 6, 2024, the Company announced that Focal One Robotic HIFU was featured at the 41st World Congress of Endourology and Uro-Technology (WCET 2024) meeting, which took place in Seoul, Korea, from August 12-16, 2024. The Company had a significant presence at WCET 2024, reflecting the increasing trend amongst urologists for utilizing non-invasive HIFU technology for the management of prostate cancer. In addition to providing hands-on Focal One simulations for urologists in attendance, this year’s WCET meeting included a featured semi-live Focal One clinical procedure conducted by Dr. Tarik Benidir, Clinical Assistant Professor from the University of Florida.

    • On June 3, 2024, the Company appointed Damien Desmedt and Alexander Fromm to further strengthen the EDAP’s European and Middle Eastern commercial leadership. Mr. Desmedt was appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm was appointed General Manager for Switzerland and will oversee several strategic European territories.

    • On May 6, 2024, the Company announced that final results from a large, prospective, multicenter, non-inferiority study, the HIFI Study, comparing Focal One® high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) were presented at the 119th American Urological Association Annual Meeting (AUA 2024), which took place from May 3-6, 2024, in San Antonio, Texas, USA. Professor Pascal Rischmann of Rangueil University Hospital in Toulouse, France, and lead investigator of the HIFI Study, highlighted the final results from the study during an oral presentation at the AUA plenary session, “Paradigm-shifting, Practice-changing Clinical Trials in Urology”.

    Clinical Pipeline Update

    Endometriosis Program

    • On July 19, 2024, the Company announced interim results from its Phase 3 study evaluating robotic HIFU for the treatment of deep infiltrating endometriosis. The interim data show that robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosis. At three months post procedure, the study’s primary endpoint of reduced acute pelvic pain in the HIFU treatment arm compared to the Sham treatment arm was not met. Significant improvements were observed across primary and secondary outcome measures (endometriosis and digestive symptoms) across the entire study population at three months. As measured by MRI, patients receiving robotic HIFU therapy experienced higher volume reductions in the endometriosis nodule as compared to patients in the Sham treatment arm. The Phase 3 study continues per protocol, with several patients initially in the Sham treatment arm having elected and already received HIFU therapy after their pelvic pain returned to baseline levels.

    Benign Prostate Hyperplasia (BPH) Program

    • On July 26, 2024, the Company received approval from the French National Agency for Medicines and Health Products Safety (ANSM) to initiate a Phase 1-2 Clinical Trial investigating Focal One Robotic HIFU in the treatment of Benign Prostate Hyperplasia (BPH). This company-sponsored multicenter study is designed as a 2-phase study: the first phase will take place at two leading academic prostate treatment centers in France with a recognized expertise in the treatment of BPH as well as in the use of Focal One HIFU technology. This first phase is designed as a HIFU dose escalation protocol aimed at defining the optimal treatment parameters to effectively treat BPH and its related symptoms with minimal side effects. The second phase of the study will expand patient enrollment across a larger number of treatment centers in order to validate the safety and efficacy of the parameters defined during the first phase of the study.

    Upcoming Meetings and Events H.C. Wainwright Healthcare Conference, Tuesday, September 10th, in New York City

    Second Quarter 2024 Results

    Total worldwide revenue for the second quarter of 2024 was EUR 15.8 million (USD 17.0 million), an increase of 10.6% as compared to worldwide revenue of EUR 14.3 million (USD 15.5 million) for the same period in 2023.

    Total revenue in the HIFU business for the second quarter of 2024 was EUR 4.8 million (USD 5.2 million), as compared to EUR 4.9 million (USD 5.3 million) for the second quarter of 2023. Three Focal One systems were sold during the second quarter of 2024 versus four systems sold in the second quarter of 2023. Despite the 1 unit decrease year over year, the Company recorded a 29.4% year-over-year growth in worldwide disposables revenues, driven by the 63% Focal One procedure growth in the US.

    Total revenue in the Distribution business for the second quarter of 2024 was EUR 8.7 million (USD 9.4 million), as compared to EUR 7.2 million (USD 7.8 million) for the second quarter of 2023. The increase in Distribution revenue was driven primarily by 12 ExactVu units sold during the second quarter of 2024 as compared to 9 units sold during the second quarter of 2023.

    Total revenue in the LITHO business for the second quarter of 2024 was EUR 2.3 million (USD 2.5 million), as compared to EUR 2.2 million (USD 2.4 million) for the second quarter of 2023. The increase in LITHO revenue was driven by 3 lithotripsy units sold in the second quarter of 2024 as compared to 2 units sold in the second quarter of 2023.

    Gross profit for the second quarter of 2024 was EUR 5.9 million (USD 6.4 million), compared to EUR 5.7 million (USD 6.1 million) for the year-ago period. Gross profit margin on net sales was 37.5% in the second quarter of 2024, compared to 39.6% for the comparable period in Q2 2023. The decrease in gross profit margin year-over-year was primarily due to product mix shift and higher cost of goods sold.

    Operating expenses were 12.1 million euros (USD 13.0 million) for the second quarter, compared to 9.9 million euros (USD 10.7 million) for the same period in 2023. The increase in operating expenses was due to the continued investments made in the global commercial and R&D functions in anticipation of growing demand for Focal One.

    Operating loss for the second quarter of 2024 was EUR 6.1 million (USD 6.6 million), compared to an operating loss of EUR 4.2 million (USD 4.6 million) in the second quarter of 2023.

    Net loss for the second quarter of 2024 was EUR 6.1 million (USD 6.6 million), or EUR (0.16) per share, as compared to net loss of EUR 4.7 million (USD 5.1 million), or EUR (0.13) per share in the second quarter of 2023.

    Year-to-Date Results

    Total worldwide revenue for the six months ended June 30, 2024, was EUR 30.7 million (USD 33.1 million), an increase of 5.6% from total worldwide revenue of EUR 29.1 million (USD 31.5 million) for the same period in 2023.

    Total revenue in the HIFU business for the six months ended June 30, 2024, was EUR 10.6 million (USD 11.4 million), an increase of 4.5% as compared to EUR 10.1 million (USD 11.0 million) for the six months ended June 30, 2023.

    Total revenue in the Distribution business for the six months ended June 30, 2024, was EUR 15.6 million (USD 16.8 million), a 11.4% increase compared to EUR 14.0 million (USD 15.1 million) for the six months ended June 30, 2023.

    Total revenue in the LITHO business for the six months ended June 30, 2024, was EUR 4.6 million (USD 4.9 million), a decrease of 8.5% from EUR 5.0 million (USD 5.4 million) for the six months ended June 30, 2023.

    Gross profit for the six months ended June 30, 2024, was EUR 12.3 million (USD 13.3 million), compared to EUR 11.7 million (USD 12.7 million), for the six months ended June 30, 2023. Gross profit margin on net sales was 40.1% for the six months ended June 30, 2024, compared to 40.2% for the comparable period in 2023.

    Operating expenses were EUR 23.3 million (USD 25.1 million) for the six months ended June 30, 2024, compared to EUR 22.5 million (USD 24.3 million) for the same period in 2023.

    Operating loss for the six months ended June 30, 2024, was EUR 11.0 million (USD 11.8 million), compared to an operating loss of EUR 10.8 million (USD 11.7 million) for the six months ended June 30, 2023.

    Net loss for the six months ended June 30, 2024, was EUR 10.7 million (USD 11.5 million), or EUR (0.29) per share, as compared to a net loss of EUR 12.2 million (USD 13.2 million), or EUR (0.33) per share for the six months ended June 30, 2023.

    As of June 30, 2024, the Company held cash and cash equivalents of EUR 30.2 million (USD 32.4 million) as compared to EUR 43.5 million (USD 48.1 million) as of December 31, 2023.

    Conference Call Information

    A conference call and webcast to discuss the second quarter 2024 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

    Date:                       Wednesday, August 28th @ 8:30am Eastern Time
    Domestic:                 1-877-300-8521
    International:              1-412-317-6026
    Passcode (Conf ID):      7219730
    Call me™:                 LINK (will be activated 15 minutes prior to scheduled start time)        

    Webcast:                 https://viavid.webcasts.com/starthere.jsp?ei=1679882&tp_key=f499a45540

    About EDAP TMS SA
    A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.

    Forward-Looking Statements
    In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

    Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

    Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

    Company Contact
    Blandine Confort
    Investor Relations / Legal Affairs
    EDAP TMS SA
    +33 4 72 15 31 50
    bconfort@edap-tms.com

    Investor Contact
    John Fraunces
    LifeSci Advisors, LLC
    (917) 355-2395
    jfraunces@lifesciadvisors.com

    EDAP TMS S.A.
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Amounts in thousands of Euros and U.S. Dollars, except per share data)

                     
        Three Months Ended   Three Months Ended
           June 30,       June 30,       June 30,       June 30, 
        2024   2023   2024   2023
        Euros   Euros   $US   $US
    Sales of medical equipment   11,118   9,804   11,948   10,657
    Net sales of RPP and leases   1,886   1,751   2,027   1,903
    Sales of spare parts, supplies and services   2,787   2,724   2,995   2,961
    TOTAL NET SALES   15,791   14,278   16,970   15,522
    Other revenues   —   —   —   —
    TOTAL REVENUES   15,791   14,278   16,970   15,522
    Cost of sales   (9,872)   (8,623)   (10,609)   (9,374)
    GROSS PROFIT   5,919   5,655   6,361   6,148
    Research & development expenses   (2,077)   (1,677)   (2,232)   (1,823)
    Selling, general & administrative expenses   (9,989)   (8,203)   (10,736)   (8,917)
    Total operating expenses   (12,066)   (9,880)   (12,967)   (10,740)
    OPERATING PROFIT (LOSS)   (6,147)   (4,225)   (6,606)   (4,592)
    Interest (expense) income, net   190   255   204   278
    Currency exchange gains (loss), net   (49)   (508)   (52)   (552)
    LOSS BEFORE INCOME TAXES   (6,005)   (4,477)   (6,454)   (4,867)
    Income tax (expense) credit   (127)   (221)   (136)   (240)
    NET LOSS   (6,132)   (4,698)   (6,590)   (5,107)
    Loss per share – Basic and diluted   (0.16)   (0.13)   (0.18)   (0.14)
    Avg number of shares used in computation of basic and diluted EPS   37,205,307   36,985,934   37,205,307   36,985,934

    NOTE: Translated to U.S. dollars at the 2024 average three months’ exchange rate of 1 Euro = 1.0747 USD, and 2023 average three months’ exchange rate of 1 Euro = 1.0871 USD

    EDAP TMS S.A.
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Amounts in thousands of Euros and U.S. Dollars, except per share data)

                     
        Six Months Ended   Six Months Ended
           June 30       June 30       June 30       June 30 
        2024   2023   2024   2023
        Euros   Euros   $US   $US
    Sales of medical equipment   21,085   20,123   22,735   21,782
    Net sales of RPP and leases   3,661   3,329   3,948   3,604
    Sales of spare parts, supplies and services   5,952   5,622   6,418   6,085
    TOTAL NET SALES   30,698   29,074   33,102   31,472
    Other revenues   —   —   —   —
    TOTAL REVENUES   30,698   29,074   33,102   31,472
    Cost of sales   (18,394)   (17,387)   (19,834)   (18,821)
    GROSS PROFIT   12,304   11,687   13,267   12,651
    Research & development expenses   (4,146)   (3,135)   (4,470)   (3,393)
    Selling, general & administrative expenses   (19,121)   (19,333)   (20,618)   (20,928)
    Total operating expenses   (23,267)   (22,467)   (25,088)   (24,321)
    OPERATING PROFIT (LOSS)   (10,963)   (10,781)   (11,821)   (11,670)
    Interest (expense) income, net   335   511   361   554
    Currency exchange gains (loss), net   187   (1,653)   202   (1,789)
    LOSS BEFORE INCOME TAXES   (10,440)   (11,922)   (11,258)   (12,905)
    Income tax (expense) credit   (238)   (267)   (257)   (289)
    NET LOSS   (10,678)   (12,189)   (11,514)   (13,194)
    Loss per share – Basic and diluted   (0.29)   (0.33)   (0.31)   (0.36)
    Average number of shares used in computation of basic and diluted EPS   37,104,348   36,954,439   37,104,348   36,954,439

    NOTE: Translated to U.S. dollars at the 2024 average six months’ exchange rate of 1 Euro = 1.0783 USD, and 2023 average six months’ exchange rate of 1 Euro = 1.0825 USD

    EDAP TMS S.A.
    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
    (Amounts in thousands of Euros and U.S. Dollars)

                     
           June 30,       December 31,       June 30,       December 31, 
        2024   2023   2024   2023
        Euros   Euros   $US   $US
    Cash, cash equivalents and short-term investments   30,212   43,471   32,361   48,087
    Accounts receivable, net   18,214   19,238   19,510   21,281
    Inventory   17,962   15,112   19,240   16,717
    Other current assets   937   659   1,004   729
    TOTAL CURRENT ASSETS   67,326   78,480   72,114   86,814
    Property, plant and equipment, net   9,976   8,193   10,686   9,063
    Goodwill   2,412   2,412   2,583   2,668
    Other non-current assets   2,453   2,464   2,628   2,725
    TOTAL ASSETS   82,167   91,548   88,011   101,270
    Accounts payable & other accrued liabilities   18,133   18,435   19,422   20,392
    Deferred revenues, current portion   4,828   4,049   5,171   4,479
    Short term borrowing   1,780   2,466   1,907   2,728
    Other current liabilities   2,705   2,646   2,897   2,927
    TOTAL CURRENT LIABILITIES   27,445   27,596   29,397   30,526
    Obligations under operating and finance leases non-current   2,246   1,315   2,406   1,454
    Long term debt, non-current   1,256   1,997   1,346   2,209
    Deferred revenues, non-current   548   643   587   712
    Other long-term liabilities   3,036   3,075   3,252   3,402
    TOTAL LIABILITIES   34,531   34,626   36,987   38,304
    TOTAL SHAREHOLDERS’ EQUITY   47,636   56,922   51,024   62,966
    TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY   82,167   91,548   88,011   101,270

    NOTE: Translated to U.S. dollars at the exchange rate of 1 Euro = 1.0711 USD, on June 30, 2024 and at the exchange rate of 1 Euro = 1.1062 USD, on December 31, 2023

    EDAP TMS S.A.
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (Amounts in thousands of Euros and U.S. Dollars)

                     
           Six Months Ended      Twelve Months Ended      Six Months Ended      Twelve Months Ended
        June 30,    December 31,    June 30,    December 31, 
        2024   2023   2024   2023
        (Euros)   (Euros)   ($US)   ($US)
    NET LOSS   (10,678)   (21,178)   (11,514)   (22,930)
    Adjustments to reconcile net loss to net cash provided by operating activities(1)   2,935   9,403   3,164   10,181
    OPERATING CASH FLOW   (7,744)   (11,775)   (8,350)   (12,749)
    Net Decrease in operating assets and liabilities   (2,192)   (2,903)   (2,364)   (3,144)
    NET CASH USED IN OPERATING ACTIVITIES   (9,936)   (14,678)   (10,714)   (15,892)
    Additions to capitalized assets produced by the company and other capital expenditures   (1,854)   (4,344)   (1,999)   (4,704)
    NET CASH USED IN INVESTING ACTIVITIES   (1,854)   (4,344)   (1,999)   (4,704)
    NET CASH USED IN FINANCING ACTIVITIES   (1,433)   (911)   (1,545)   (986)
    NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS   (35)   268   (1,467)   2,130
    NET DECREASE IN CASH AND CASH EQUIVALENTS   (13,258)   (19,666)   (15,726)   (19,452)

    (1) including share-based compensation expenses of Euro 1,502 thousand for the six months ended June 30, 2024 and Euro 6,865 thousand for the full year ended December 31, 2023.

    NOTE: Translated to U.S. dollars at the 2024 average six months’ exchange rate of 1 Euro = 1.0783 USD, and 2023 average twelve months’ exchange rate of 1 Euro = 1.0827 USD

    EDAP TMS S.A.
    UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
    Six months ended June 30, 2024
    (Amounts in thousands of Euros)

                                           
           HIFU                ESWL                Distribution                Reconciling      Total After            
        Division       Division       Division       Items   Consolidation      
    Sales of goods   6,335        1,718        13,032        —   21,085       
    Sales of RPPs & leases   3,004        533        124        —   3,661       
    Sales of spare parts & services   1,239        2,301        2,412        —   5,952       
    TOTAL NET SALES   10,577        4,553        15,569        —   30,698       
    Other revenues   —        —        —        —   —       
    TOTAL REVENUES   10,577        4,553        15,569        —   30,698       
    GROSS PROFIT (% of Net Sales)   4,993   47.2 %   2,034   44.7 %   5,278   33.9 %   —   12,304   40.1 %
    Research & development expenses   (3,623)        (216)        (307)        —   (4,146)       
    Selling, general & administrative expenses   (10,846)        (914)        (5,143)        (2,218)   (19,121)       
    OPERATING PROFIT (LOSS)   (9,477)        904        (173)        (2,218)   (10,963)       

    Attachment


    Primary Logo

シェアする